To report an adverse event or product quality issue, please email us at reportnow@argenx.com or call us at 1-833-274-9411.
©2026 argenx | Disclaimer | Privacy Policy | Regulations | U.S. Supplemental Privacy Notice
David L. Lacey
Strategic Advisor to the R&D Committee
Dr. David L. Lacey served as a Director of argenx from 2014 to 2021, when he transitioned to an advisory role. He has been a biopharmaceutical consultant since 2011, where he advises academic institutions, biotechnology companies, and venture capital firms.
From 1994 until his retirement in 2011, he held various positions, including Head of Discovery Research, at Amgen Inc., where he played a fundamental scientific role in the discovery of the OPG/RANKL/RANK pathway, which led to the development of the anti-RANKL human mAb denosumab, for both osteoporosis (Prolia) and cancer-related bone diseases (XGEVA).
He holds a Bachelor’s degree in biology and an M.D. from the University of Colorado, and has his board certification in anatomic pathology.
|
Nationality |
USA |
Explore More
At argenx, every piece of the innovation story connects. See where it leads next.
Grants
Funding research, education, and initiatives that raise the standard of care.
About Us
Discover why we’re more than a unique name.
Newsroom
The latest news and press releases from argenx.
